by Emily Burke, PhD | Jan 30, 2019 | Metabolic & Cardiovascular Disease
Matters Of The Heart The words “heart failure” might bring to mind a chubby businessman clutching his chest and keeling over at the steakhouse. The reality is more nuanced. Medically, the phrase refers to a chronic condition that affects multitudes. Nearly 6 million... 
by Emily Burke, PhD | Jan 17, 2019 | Metabolic & Cardiovascular Disease
Fighting A Silent Epidemic Consider the liver. It’s just one of the jumble of stuff inside that makes us tick, right? What do you really know about it though—other than it’s “vital”? In fact, the liver is your largest internal organ, and plays vital roles in... 
by Emily Burke, PhD | Jul 13, 2017 | Metabolic & Cardiovascular Disease
MEDS FOR THINNER BLOOD CAN EQUAL FEWER CLOTS, BUT HOW? The FDA’s recent approval of Portola Pharmaceuticals’ (South San Francisco, CA) new blood thinner drug Bevyxxa paved the way for the prevention of blood clots in patients hospitalized for... 
by Emily Burke, PhD | Nov 10, 2016 | Metabolic & Cardiovascular Disease
Targeting Fat Obesity is considered one of the most pressing public health issues of the day. According to the Center for Disease Control, 37% of adults and 17% of children in the U.S. are obese. The latest drug interventions work by attempting to suppress food... 
by Emily Burke, PhD | Feb 16, 2016 | Metabolic & Cardiovascular Disease
Identifying Gut Proteins To Tackle Metabolic Disorders Historians of science love to tell about “eureka moments”—simple observations leading to major insight. Greek mathematician Archimedes allegedly exclaimed the original “Eureka!”—meaning “I have found it!”—upon... 
by Emily Burke, PhD | Jun 25, 2015 | Metabolic & Cardiovascular Disease
$23 Billion Blockbuster? The PCSK9 inhibitor buzz keeps rolling, especially since sitting before the FDA Advisory Committee earlier this month. Amgen’s (Thousand Oaks, CA) Repatha and Sanofi’s (Paris, France) Praluent are a new class of cholesterol lowing... 
